Hursting MJ - Search Results

1

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.

Young G, Boshkov LK, Sullivan JE, Raffini LJ, Cox DS, Boyle DA, Kallender H, Tarka EA, Soffer J, Hursting MJ. Young G, et al. Among authors: hursting mj. Pediatr Blood Cancer. 2011 Jul 1;56(7):1103-9. doi: 10.1002/pbc.22852. Epub 2010 Nov 5. Pediatr Blood Cancer. 2011. PMID: 21488155

2

Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.

Hursting MJ, Soffer J. Hursting MJ, et al. Drug Saf. 2009;32(3):203-18. doi: 10.2165/00002018-200932030-00003. Drug Saf. 2009. PMID: 19338378 Review.

3

Argatroban anticoagulation in pediatric patients: a literature analysis.

Hursting MJ, Dubb J, Verme-Gibboney CN. Hursting MJ, et al. J Pediatr Hematol Oncol. 2006 Jan;28(1):4-10. doi: 10.1097/01.mph.0000195296.48319.38. J Pediatr Hematol Oncol. 2006. PMID: 16394885 Review.

4

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.

Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Reddy BV, et al. Among authors: hursting mj. Ann Pharmacother. 2005 Oct;39(10):1601-5. doi: 10.1345/aph.1G033. Epub 2005 Aug 30. Ann Pharmacother. 2005. PMID: 16131539 Clinical Trial.

5

Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.

Levine RL, Hursting MJ, McCollum D. Levine RL, et al. Among authors: hursting mj. Chest. 2006 May;129(5):1167-75. doi: 10.1378/chest.129.5.1167. Chest. 2006. PMID: 16685006

6

Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor.

LaMonte MP, Brown PM, Hursting MJ. LaMonte MP, et al. Among authors: hursting mj. Expert Rev Cardiovasc Ther. 2005 Jan;3(1):31-41. doi: 10.1586/14779072.3.1.31. Expert Rev Cardiovasc Ther. 2005. PMID: 15723573 Review.

7

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Lewis BE, et al. Among authors: hursting mj. Arch Intern Med. 2003 Aug 11-25;163(15):1849-56. doi: 10.1001/archinte.163.15.1849. Arch Intern Med. 2003. PMID: 12912723 Clinical Trial.

8

Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.

Matthai WH Jr, Hursting MJ, Lewis BE, Kelton JG. Matthai WH Jr, et al. Among authors: hursting mj. Thromb Res. 2005;116(2):121-6. doi: 10.1016/j.thromres.2004.11.006. Epub 2004 Dec 8. Thromb Res. 2005. PMID: 15907526 Clinical Trial.

9

Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).

Bartholomew JR, Hursting MJ. Bartholomew JR, et al. Among authors: hursting mj. J Thromb Thrombolysis. 2005 Jun;19(3):183-8. doi: 10.1007/s11239-005-1849-9. J Thromb Thrombolysis. 2005. PMID: 16082605 Clinical Trial.

10

Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.

LaMonte MP, Brown PM, Hursting MJ. LaMonte MP, et al. Among authors: hursting mj. Crit Care Med. 2004 Apr;32(4):976-80. doi: 10.1097/01.ccm.0000119426.34340.e2. Crit Care Med. 2004. PMID: 15071388

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters